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Background and purpose: Mutations in fused in sarcoma (FUS) were recently iden-
tified as a cause of familial amyotrophic lateral sclerosis (ALS). The frequency of
occurrence of mutations in FUS in sets of patients with familial ALS remains to be
established.
Methods: We sequenced the FUS gene in a cohort of patients with familial ALS seen
at the neuromuscular clinic in Leuven. A total of 28 patients with SOD1-negative ALS
from 22 families were analyzed.
Results: We identified a R521H mutation in 4 patients, belonging to a kindred of
dominantly inherited classical ALS. The mutation segregated with disease. Mutations
in FUS were observed in 2.9% of ALS pedigrees in our cohort.
Conclusions: These results show that mutations in FUS are also a significant cause of
familial ALS in Belgium.
Amyotrophic lateral sclerosis (ALS) is a neurodegen-
erative disorder of motor neurons, in which a progres-
sive paralysis and atrophy of muscles usually limits
survival after disease onset to 2–5 years. In 10% of
cases, it is an inherited disease. Mutations in the
superoxide dismutase 1 (SOD1) gene are the most fre-
quent genetic cause of ALS, responsible for 20%. In
the majority of familial ALS cases, the underlying gene
defect remains unknown. Recently, mutations in the
gene FUS (fused in sarcoma)/TLS (translocated in
liposarcoma) were discovered as a cause of ALS [1,2].
To date, 14 mutations have been identified in FUS. For
five of them, clear segregation with the disease was
shown. Most mutations are missense mutations in exon
14 or 15 and give rise to classical ALS, without cogni-
tive decline. In the original studies, FUSmutations were
found in about 3 to 5% of patients with familial ALS,
but not in sporadic patients with ALS or healthy con-
trols [1,2]. In an Italian study, two known FUS muta-
tions have been observed in two different ALS families
[3]. Mutations are inherited mostly in an autosomal
dominant manner, except for the recessive mutation
found in a family from Cape Verdean origin. The fre-
quency of FUS mutations in other familial ALS pop-
ulations remains unknown. Therefore, we sequenced
FUS in a set of patients with SOD1-negative ALS from
Belgian origin.
Subjects and Methods
Study population
Between 1994 and 2008, DNA samples from patients
with familial ALS seen at the neuromuscular clinic in
Leuven were collected. Patients met the revised El
Escorial criteria for diagnosis of ALS. Blood samples
were obtained after informed consent, and this study
was approved by the local ethical committee of the
K.U. Leuven. Samples from a total of 82 patients with
familial ALS, from 34 different families were collected.
The FUS gene was investigated in 28 patients from 22
families in which no mutations in SOD1 [4,5], TDP-43
[6] or angiogenin were found.
FUS analysis
DNA was extracted from venous blood using standard
methods. The 15 exons and exon–intron boundaries of
FUS were amplified by PCR. To facilitate sequencing,
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the M13 forward primer sequence and the M13 reverse
primer sequence were attached to the FUS primers.
Sequencing of first-round PCR products was performed
on an automated sequencer ABI 3130XL Genetic
Analyzer (Applied Biosystems, Foster City, CA, USA).
Results
We sequenced FUS in all familial ALS cases, from
previously unexplained pedigrees. Patient characteris-
tics are summarized in table 1. In four members from
family FALS13 (Fig. 1a), we identified a mutation at
position 521 (p.R521H) because of a c.1562G>A base-
pair change in exon 15 (Fig. 1b).
The R521H mutation was observed in four affected
family members from two different generations and
segregated with the disease in this family. The ALS
symptoms always started in the limbs, with mild upper
motor neuron signs and no cognitive decline. Disease
onset varied widely. All patients fulfilled the revised El
Escorial criteria for definite ALS at presentation.
The first generation was characterized by the occur-
rence of ALS in a 50-year-old woman (subject I:1),
which limited survival to 52 years. She had four chil-
dren, of whom three developed ALS later in life. Sub-
ject II:4 presented with muscle weakness and wasting of
the left arm at the age of 60, with fasciculations and
mild hyperreflexia. There was a steady progression, and
she died at the age of 63. Her two older brothers
(subjects II:1 and II:3) previously died of ALS. Both of
them had an onset of disease in the limbs. One 71-year-
old sister was not affected and did not carry the
mutation (subject II:2). The three affected patients from
this generation all had children and grandchildren. One
patient from the third generation (subject III:6) died at
the age of 47, 3 years after muscle weakness, and
atrophy was first noted in the left arm. Subject III:11,
also a R521H mutation carrier, currently has ALS
Table 1 Patient characteristics of familial
ALS patients in which ALS gene mutations
were previously excluded Family
ID Inheritance Sex
Onset
age
(year)
Limb/
Bulbar
Frontotemporal
dementia
Survival
(months)
FALS3 AD M 47 L ) 7
FALS3 AD M 40 B ) 22
FALS3 AD F ? ? ) ?
FALS4 ? F 58 B ) 19
FALS5 AD F 66 B + 23
FALS6 AD M 59 B ) 16
FALS7 ? M 49 L ) 14
FALS7 ? M 54 L ) 17
FALS8 ? M 54 B + 33
FALS8 ? F 66 B + 35
FALS9 ? M 52 L ) 43
FALS9 ? F 40 L ) 85
FALS10 ? F 44 L ) Alive
FALS13 AD F 44 L ) 38
FALS13 AD M 65 L ) 60
FALS13 AD F 60 L ) 37
FALS13 AD M 49 25
FALS13 AD F 33 L ) Alive
FALS14 ? M 55 L ) 24
FALS15 ? F 60 B ) 14
FALS22 AD M 56 L ) Alive
FALS24 AD M 52 L ) Alive
FALS25 ? M 48 L ) 10
FALS25 ? M 61 B ) 35
FALS27 ? M 57 L ) 4
FALS32 ? M 72 L ) 78
FALS34 ? V 77 L ) 17
FALS35 AD V 50 L ) 43
FALS36 AD V 50 B ) 30
FALS39 ? M 65 L ) Alive
FALS40 ? M 61 L ) Alive
FALS41 AD M 57 B ) 24
Patient characteristics of patients with familial ALS; ALS, amyotrophic lateral sclerosis;
AD, autosomal dominant; AR, autosomal recessive; M, male; F, female; L, limb; B, bulbar.
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which started at the age of 33 years, with paresis in the
left leg.
Discussion
Over the last year, two novel ALS genes have been
identified: TDP-43 [7,8] and more recently, FUS [1,2].
Both genes encode a DNA/RNA-binding protein with
mainly nuclear localization. Mutations in FUS have
been reported in families from the UK, USA, Cape
Verde and Italy, but their contribution to familial ALS
pathogenesis in other populations remains to be
established. In this study, we screened for mutations in
FUS in patients with familial ALS, seen at the neuro-
muscular clinic in Leuven. A R521H mutation, previ-
ously reported in the original studies [1,2], was found in
4 patients with ALS from a pedigree with autosomal
dominant ALS. The mutation segregated with the dis-
ease in this family. In our cohort of familial ALS (82
patients from 34 families), mutations in SOD1 are
responsible for 32.4%, mutations in TDP-43 for 2.9%
and mutations in FUS also for 2.9% of ALS families.
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Figure 1 R521H mutation in a Belgian
pedigree with familial amyotrophic lateral
sclerosis. The heterozygous 1562G>A
mutation in an affected patient from
generation 2 and a non-affected sister (a).
Pedigree of family FALS13 (b). The first 3
generations of this pedigree are depicted
[affected members in black, unaffected
members in white, genotypes as indicated
if DNA was available, age of onset (O),
death (D)].
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